By PPN News Staff
The FDA approved the oral antiviral nirmatrelvir+ritonavir (Paxlovid, Pfizer) to treat mild to moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
Nirmatrelvir+ritonavir is the fourth drug—and the first oral antiviral pill—approved by the FDA to treat COVID-19 in adults.
Nirmatrelvir+ritonavir, manufactured and packaged under the emergency use authorization and distributed by the Department of